AISAP Cardio vs Imbio PHA (4.0.0)
AI Verdict
Choose AISAP Cardio if…
Choose AISAP Cardio if you require rapid, comprehensive cardiac diagnostic assessments and measurements directly at the patient's bedside using point-of-care ultrasound. This tool is ideal for early detection of structural heart disease and heart failure, providing immediate AI-powered interpretation of various cardiac parameters and valvular pathologies.
View AISAP Cardio →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if your primary need is automated analysis of CT pulmonary angiogram (CTPA) scans to assess right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. This software excels at precisely measuring cardiac structures from existing CT images and calculating critical ratios like RV/LV and PA/Ao.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AISAP Cardio | Imbio PHA (4.0.0) |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud-based | Cloud, Enterprise (on-premise), or via partners |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AISAP CardioAISAP Cardio focuses on point-of-care (POCUS) and bedside use, enabling non-cardiologists to perform and interpret cardiac assessments with accuracy comparable to experts after minimal training. Its integration into existing clinical workflows and emphasis on rapid, real-time diagnosis directly at the patient's side makes it highly accessible and user-friendly for a broader range of clinicians. Imbio PHA, while automated and integrated into radiology workflows, operates on CT scans, which is a less immediate patient interaction point.
Clinical Value
AISAP CardioBoth tools are FDA-cleared and offer significant clinical value. However, AISAP Cardio provides a broader and more comprehensive cardiac diagnostic assessment at the point of care, including detailed analysis of valvular pathologies, LVEF, and ventricular dimensions, crucial for early detection of structural heart disease and heart failure. It has been validated to improve clinician performance and enable non-cardiologists to interpret POCUS accurately. Imbio PHA is highly valuable for its specialized application in assessing right ventricular dilation from CTPA for pulmonary embolism and hypertension, but its scope is more focused.
Pricing & Value
TieNeither AISAP Cardio nor Imbio PHA publicly discloses its pricing information. Both require potential customers to contact them directly for demos and pricing details. Without transparent pricing, it is impossible to conduct a head-to-head comparison on this dimension.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA demonstrates stronger enterprise readiness by explicitly stating HIPAA compliance with third-party certification and offering flexible deployment options, including cloud, enterprise (on-premise), or via partners. The option for on-premise installation within a hospital's firewall is often critical for larger healthcare systems with specific security and data governance requirements. While AISAP Cardio mentions a 'HIPAA-compliant and ISO-certified cloud,' Imbio's explicit third-party certification and on-premise offering provide greater assurance for enterprise adoption.
Innovation
AISAP CardioAISAP Cardio exhibits a higher degree of innovation by bringing expert-level cardiac diagnostics to the point of care through AI-powered POCUS, enabling non-specialists to accurately interpret complex cardiac conditions from a single ultrasound view. This 'Point-of-Care Assisted Diagnosis (POCAD)' approach significantly enhances accessibility and early detection, representing a more transformative shift in healthcare delivery. Imbio PHA's automation of CTPA analysis is valuable but represents an advancement within a more established imaging modality.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA provides clear and accessible support resources, including dedicated phone and email support, an online case submission form, and specified support hours. It also directs users to a specific location for user manuals and product documentation. AISAP Cardio's publicly available information lacks this level of detail regarding its support infrastructure and documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AISAP Cardio | Imbio PHA (4.0.0) |
|---|---|---|
| Primary Use Case | Rapid, comprehensive cardiac diagnostic assessments and measurements, enabling early detection of structural heart disease and heart failure at the bedside. | Measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. |
| Input Imaging Modality | Point-of-care ultrasound (POCUS) | CT pulmonary angiogram (CTPA) scans |
| Key Cardiac Measurements | Left Ventricle Ejection Fraction (LVEF), right and left ventricular dimensions, atrial areas, ascending aorta diameter, IVC diameter, valvular pathologies (mitral, tricuspid, aortic regurgitation, aortic stenosis). | Right and left ventricle diameters, main pulmonary artery and aorta diameters, RV/LV and PA/Ao ratios. |
| Output Formats | Automated generation of analyses, interpretations, and reports. | Annotated DICOM images, summary reports in PDF format. |
| Categories | Cardiology AI | Cardiology AI, Radiology & Imaging AI |
Videos
Demos, reviews, and walkthroughs featuring AISAP Cardio and Imbio PHA (4.0.0).